Education and Training
Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects
Determine the benefit of oral vancomycin therapy for Primary Sclerosing Cholangitis.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Oral Vancomycin
Eligibility
Inclusion Criteria:
- PSC Diagnosis: Liver biopsy and/or imaging (MRCP, ERCP, CT, or US
- Colonoscopy within 1 year or starting of study
- 2 groups:
1. IBD (Inflammatory bowel disease) and PSC: details of extent and type of IBD
2. No IBD and PSC, but positive p-ANCA or ASCA serologies indicating possible IBD.
Exclusion Criteria:
- Allergy to Vancomycin
- PSC not associated with IBD or NO positive IBD antibodies (p-ANCA [anti- neutrophil
cytoplasmic antibody] or ASCA [anti-Saccharomyces cerevisiae antibody])
- Cholangiocarcinoma
- On oral or topical (enemas or suppositories) corticosteroids,topical mesalamine, or
biologics (infliximab, adalimumab, certolizumab).
Ages Eligible for Study
1 Year - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Ken Cox, MD
650-721-2250
Not Recruiting